Available Across All 50 US States, Extending Deep Longevity’s AI-Powered Ageing Science Directly to Consumers for a Second Growth Curve HONG KONG, Sept. 28, 2026 /PRNewswire/ — Regent Pacific Group Limited (“Regent Pacific” or the “Company“, together with its subsidiaries, the “Group“; stock code: 0575.HK), is pleased to announce that Deep Longevity, its AI-powered biological ageing […]
Clinical Milestone Expands Development of Paxalisib Beyond Oncology and Triggers $2 Million Payment to Kazia SYDNEY, Sept. 22, 2026 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that Sovargen Co., Ltd., a biotechnology company specializing in central […]
NEW YORK and SUZHOU, China, Sept. 20, 2026 /PRNewswire/ — Accro Bioscience Inc. (Accro Bio), a clinical-stage biotechnology company pioneering the development of novel therapeutics for immune mediated diseases, today announced the dosing of their first patient in the Phase IIb clinical trial of AC-101, a selective RIPK2 inhibitor, in patients with moderate-to-severe ulcerative colitis […]
Bupa Hong Kong has welcomed the city's First Five-Year Plan and the health measures announced in the latest Policy Address. The insurer praised the government's emphasis on stronger primary healthcare and prevention. It also backed faster adoption of digital health and policies that support healthy ageing. Bupa said the plan's direction lines up with its own goal of building a healthier Hong Kong.
The Ministry of Health has ordered Dr. Nith Beauty Center, a local beauty clinic chain, to suspend its medical services after an inspection found the Vientiane facility performing injections and other medical procedures without ministry authorization. Ordered on 2 September, the suspension notice followed an inspection of the center in Vientiane Capital conducted with relevant […]
Multicenter study to evaluate paxalisib plus gemcitabine for children and young adults with recurrent or progressive AT/RT, where no approved therapies currently exist SYDNEY, Sept. 9, 2026 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA) (“Kazia” or the “Company”), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, […]
As the global wellness real estate market is projected to reach USD 1.8 trillion by 2030, WellEra introduces a new perspective on residential investment—where value is measured not only by location, design and financial returns, but also by how well a home supports healthier, longer living. By integrating healthier indoor environments, circadian-friendly lighting, acoustic and […]
SINGAPORE – Media OutReach Newswire – 5 September 2026 –The Islands Healthcare Complex – Macao Medical Center of Peking Union Medical College Hospital (hereinafter referred to as “Macao Union Medical Center”)joined the delegation led by Sam Hou Fai, Chief Executive of the Macao Special Administrative Region, on a visit to Singapore, Indonesia and Malaysia from […]
FDA clearance enables initiation of a Phase 1 clinical trial and advances the first AD2C-generated candidate into clinical development ALAMEDA, Calif. and TAIPEI, Sept. 4, 2026 /PRNewswire/ — Acepodia (6976: TT), a clinical-stage biotechnology company developing next-generation cell therapies and antibody-drug conjugates, today announced that the U.S. Food and Drug Administration (FDA) has cleared the […]
SHANGHAI, Sept. 3, 2026 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that China’s National Medical Products Administration (NMPA) has approved CARDAMYST® (etripamil) for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm […]
On 27 August, the Vientiane Province People’s Court sentenced 14 people for drug trafficking and murder, with punishments ranging from two years to life in prison. The court gave its toughest sentence to a 27 year old laborer from Mai village, Phonhong district. The judges sentenced him to life in prison and a LAK 500 […]
Kazia Therapeutics is expanding its paxalisib clinical trial to include HR+/HER2- breast cancer. Preclinical data show the drug combined with standard care is well tolerated and produces significant antitumor activity. The expansion will add a three-arm study evaluating paxalisib plus fulvestrant, with or without palbociclib, against standard care. First patient is expected by end of 2026, with full enrollment by end of 2027.
Apical, through its subsidiary PT Sari Dumai Oleo, provided free health screenings and treatment to more than 60 residents of Lubuk Gaung in Dumai, Riau. The event took place at the grounds of Pon An Kiong. The initiative aims to bring basic healthcare services closer to the local community.
TrueHealth Medical saw its first-half revenue surge more than 30-fold. A national charging framework for surgical robots was set up earlier this year, clearing billing hurdles for hospitals. That's opened the door for faster adoption of domestic surgical robots, and the company is now in accelerated commercialization.